

Regimen Reference Order – CUTA – trametinib + daBRAFeinib (Adjuvant)

ARIA: CUTA - [trametinib + daBRAFeinib (ADJ)]

Planned Course: Until disease progression or unacceptable toxicity up to a maximum of one year (1 cycle = 30 days)

Indication for Use: Melanoma BRAF mutation positive, Resected, Adjuvant

Proceed with treatment if:

- **ANC equal to or greater than $1.2 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$**
- **ALT less than 3 times the upper limit of normal**
- **Total bilirubin less than 2 times the upper limit of normal**
- **Creatinine clearance equal to or greater than 30 mL/minute**
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – CUTA – trametinib + daBRAFeinib (Adjuvant)

Drug	Dose	CCMB Administration Guideline
trametinib	2 mg	Orally once daily on an empty stomach To be taken at the same time as morning dose of daBRAFeinib Swallow whole (Self-administered at home)
daBRAFeinib	150 mg	Orally twice daily on an empty stomach Swallow whole (Self-administered at home)

trametinib (Mekinist®) available dosage strengths: 0.5 mg and 2 mg tablets
Classification: Cytotoxic, Hazardous
 daBRAFeinib (Tafinlar®) available dosage strengths: 50 mg and 75 mg capsules
Classification: Cytotoxic, Hazardous

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, electrolytes, liver enzymes, total bilirubin and blood glucose as per Physician Orders
- Clinical skin toxicity and nail assessment
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated

Cardiac monitoring (EKG and Left Ventricular Ejection Fraction [LVEF])

- Baseline
- Every 3 to 6 months during treatment as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

INSTRUCTIONS FOR PATIENT

- Serious non-infectious fever can occur. Patients should be instructed to contact their cancer team if they develop any fever greater than **39.5 degrees Celsius** or any fever with chills
- trametinib and daBRAFeNib should be taken on an empty stomach with a glass of water at least one hour before or two hours after a meal
- Evening dose of daBRAFeNib should be taken approximately 12 hours after morning dose
- This regimen has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- trametinib is stored in the refrigerator. The desiccant should not be removed
- daBRAFeNib is stored at room temperature
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on trametinib and daBRAFeNib

ADDITIONAL INFORMATION

- Serious febrile drug reactions may occur and may be accompanied by severe rigors or chills, dehydration, hypotension or renal failure (in the absence of infection). Corticosteroids may be required to manage pyrexia
- This regimen can prolong QT interval and PR interval
- trametinib has been associated with interstitial lung disease and pneumonitis
- trametinib and daBRAFeNib have been associated with ocular toxicity
- trametinib and daBRAFeNib are dispensed by CCMB pharmacy